What does interferon alfa-2a do?
INTERFERON ALFA-2a (in ter FEER on AL fa 2 a) (Roferon-A) helps the immune system fight viral infections such as chronic hepatitis C, and certain cancers like Philadelphia chromosome positive chronic myelogenous leukemia, and hairy cell leukemia.
Does Pegasys cause liver damage?
PEGASYS can cause serious side effects including: blood problems, thyroid problems, blood sugar problems, serious eye problems, serious liver problems, worsening of liver problems including liver failure and death, lung problems, inflammation of the pancreas, inflammation of the intestines, serious allergic reactions …
Can peginterferon alfa-2a cause dizziness?
Peginterferon alfa-2a used together with ribavirin may affect your child’s growth. Your doctor may need to check your child’s height and weight during and after treatment with these medicines. This medicine may cause some people to become drowsy, dizzy, or less alert than they are normally.
Is interferon a chemo drug?
Interferon-alfa2b is different than a chemotherapy drug; it is actually a natural part of your body’s immune system. It is known as a cytokine, which are chemicals normally secreted by cells called leukocytes in response to a virus, bacteria, or other foreign intruders.
Is interferon used for Covid?
Interferon beta-1a has been approved by the Food and Drug Administration (FDA) to treat relapsing forms of multiple sclerosis, and it has been evaluated in clinical trials for the treatment of COVID-19.
What is interferon alfa-2a (Roferon-A)?
Interferon alfa-2a (Roferon-A) was delisted from 1 December 2020 to allow time for residual supplies of this product to be dispensed and claimed for. 1 July 2020 – Pegylated interferon alfa-2a Special Authority criteria widened to include myeloproliferative disorder and cutaneous T cell lymphoma
What is interinterferon alfa-2a?
Interferon alfa-2a is produced biosynthetically using recombinant DNA technology, and is the product of a cloned human leukocyte interferon gene inserted into and expressed in E. coli. INDICATIONS AND CLINICAL USE Chronic Hepatitis C (CHC) PEGASYS (peginterferon alfa-2a) is indicated for the treatment of Chronic Hepatitis C in:
What is pegylated interferon alpha-2a?
Pegasys (Hoffmann-La Roche) Hoffmann-La Roche has developed a PEGylated interferon alpha-2a, Pegasys, for the potential treatment of chronic hepatitis C and hepatitis B virus infection. It was first approved in Switzerland in August 2001 [418260] and was expected to be launched in September/October 2001 [419333].
Is interferon alfa-2a no longer used to treat hepatitis C?
PHARMAC understands that interferon alfa-2a is no longer used to treat hepatitis C. PHARMAC has widened access to pegylated interferon alfa-2a so that patients currently taking interferon alfa-2a can access an appropriate alternative. This took effect from 1 July 2020.